Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition